This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Antiphospholipid syndrome항인지질증후군

ICD-10: D68.6 | Synonyms: Antiphospholipid antibody syndrome, APS, Hughes syndrome, lupus anticoagulant syndrome

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Early discovery and naming

The history of antiphospholipid syndrome dates back to the 1950s, when a tendency toward thrombosis and miscarriage was observed in a group of patients with false-positive syphilis serology (VDRL). In 1952, Conley and Hartmann described a substance in the plasma of patients with systemic lupus erythematosus (SLE) that prolonged the prothrombin time (PT) and partial thromboplastin time (PTT), which was later named lupus anticoagulant (LA). The paradoxical property that, unlike its anticoagulant effect in vitro, it actually causes thrombosis in vivo gradually came to be recognized.

Identification of antibodies and establishment of clinical associations

In 1983, Graham Hughes, Aziz Gharavi, and colleagues in the UK systematically described the clinical significance of anticardiolipin antibodies (aCL) in patients with and without systemic lupus erythematosus and proposed the disease as an independent syndrome. Since 1987, the syndrome has also been called 'Hughes syndrome' after Graham Hughes. Diagnostic criteria were first formally proposed at an international workshop held in Sapporo, Japan, in 1999, and were revised in 2006 as the Sydney criteria (Miyakis criteria), which remain in international use today.

Discovery of anti-beta2-glycoprotein I antibodies

In the early 1990s, McNeil and colleagues showed that the main target antigen of anticardiolipin antibodies is not cardiolipin itself but β2-glycoprotein I (β2GPI). This discovery was a landmark turning point in understanding the pathogenesis of antiphospholipid syndrome and led to the inclusion of anti-β2GPI antibodies as an independent diagnostic criterion.

2. Causes

Types and roles of antiphospholipid antibodies

Antiphospholipid syndrome is an autoimmune disease in which autoantibodies against phospholipid-binding proteins, particularly β2-glycoprotein I (β2GPI) and prothrombin, are repeatedly detected and cause thrombosis or pregnancy complications. The major antiphospholipid antibodies include lupus anticoagulant (LA), anticardiolipin antibodies (aCL IgG/IgM), and anti-beta2-glycoprotein I antibodies (anti-β2GPI IgG/IgM).

Primary vs. secondary

Primary APS occurs independently without other autoimmune disease. Secondary APS occurs in association with systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjögren syndrome, and other autoimmune diseases, with SLE being the most common association. Antiphospholipid antibodies are detected in about 30–40% of patients with SLE, and clinical APS develops in some of them.

Triggering factors

Infections (syphilis, HIV, hepatitis B/C, parvovirus), certain drugs (hydralazine, quinidine, chlorpromazine), and malignancies can induce the production of antiphospholipid antibodies. However, such cases are known to be transient with a low risk of thrombosis, and antibody positivity often disappears on retesting after 12 weeks.

3. Genetics

Genetic predisposition

Antiphospholipid syndrome is not a single-gene disorder, and a multifactorial genetic predisposition is involved. Associations with HLA types have been reported, and HLA-DR4, HLA-DR7, HLA-DQ6, HLA-DQ7, and others have been suggested to be associated with the production of anticardiolipin antibodies and anti-beta2-glycoprotein I antibodies.

β2GPI gene polymorphisms

There are studies suggesting that polymorphisms in the β2GPI gene (APOH gene, located at 17q23-24) may be associated with the risk of developing APS. In particular, the Val247Leu polymorphism has been reported in some studies to be associated with anti-β2GPI antibody production and thrombosis risk. However, no single-gene variant causing APS has been identified to date.

Family history and twin studies

Some family studies have reported familial clustering of APS, but it does not follow a simple Mendelian inheritance pattern. There are reports that the rate of antiphospholipid antibody positivity in first-degree relatives of patients with APS is higher than in the general population. A family history of autoimmune disease in general may increase the risk of developing APS.

4. General epidemiology

Worldwide prevalence

The prevalence of antiphospholipid antibodies in the general population is estimated at about 1–5%. However, not all antibody positivity meets the diagnostic criteria for clinical APS. The prevalence of clinical APS is estimated at about 50 per 100,000 population, with an annual incidence of about 2–5 per 100,000.

Sex and age distribution

APS occurs more commonly in women, with a female-to-male ratio of about 3–5:1. The age of onset is highest during the reproductive years of 15–50, but it can also occur in children and the elderly. In men, arterial thrombosis (stroke, myocardial infarction) is relatively more common.

Status in Korea

In Korea, APS is classified as a rare autoimmune disease, and accurate prevalence statistics are lacking. According to registry studies of the Korean College of Rheumatology and the Korean Society of Hematology, antiphospholipid antibodies are detected in about 20–30% of patients with SLE. In Korea as well, differentiation of APS in patients with unexplained thrombosis and recurrent miscarriage is recognized as important, and early diagnosis is increasing as access to diagnosis improves.

Frequency in recurrent thrombosis and pregnancy loss

Antiphospholipid antibodies are reported to be detected in about 10–15% of patients with unexplained arterial thrombosis, about 10–20% of patients with venous thromboembolism, and about 15–20% of women with recurrent miscarriage. There are also studies showing that APS accounts for about 20% of stroke patients of young age.

5. Pathophysiology

Anti-β2GPI antibodies and promotion of thrombosis

β2GPI is a protein that binds to anionic phospholipids and regulates coagulation reactions. Anti-β2GPI antibodies recognize β2GPI when it is bound to phospholipid membranes or endothelial cell surfaces and induce endothelial cell activation, platelet activation, and increased monocyte tissue factor expression. This promotes thrombus formation.

The paradox of the in vitro anticoagulant effect and in vivo prothrombotic effect of lupus anticoagulant

Lupus anticoagulant inhibits phospholipid-dependent coagulation reactions in vitro but actually causes thrombosis in vivo. This is because it promotes thrombus formation by inhibiting the function of anticoagulant proteins (protein C, protein S, antithrombin), inhibiting fibrinolysis, and activating endothelial cells.

Complement activation and placental damage

Complement activation plays an important role in the development of pregnancy-related complications. Antiphospholipid antibodies activate complement (C3a, C5a) in the placenta, causing trophoblast damage, neutrophil infiltration, and inflammatory responses, which are the mechanisms of early pregnancy loss and late pregnancy complications.

Platelet activation

Anti-β2GPI antibodies directly activate platelets via the platelet surface apoER2 receptor or GPIbα, contributing to increased platelet aggregation and promotion of thrombus formation. This multi-pathway promotion of thrombosis is at the core of the mechanism of thrombosis in APS.

6. Symptoms

Thrombosis-related symptoms

Venous thrombosis (deep vein thrombosis, pulmonary embolism) is the most common, with leg swelling, pain, redness, sudden dyspnea, and chest pain as the main symptoms. Arterial thrombosis includes stroke (including transient ischemic attack), myocardial infarction, and peripheral arterial occlusion. When stroke occurs at a young age, APS should be strongly suspected. Atypical thrombosis (mesenteric thrombosis, adrenal thrombosis, retinal thrombosis) may also occur.

Obstetric complications

Recurrent miscarriage (before 10 weeks of gestation, 3 or more times), unexplained fetal death after 10 weeks of gestation, and preterm delivery before 34 weeks of gestation (due to preeclampsia, eclampsia, or severe placental insufficiency) are characteristic. Intrauterine growth restriction and oligohydramnios may also occur during pregnancy. Obstetric APS results in recurrent pregnancy loss without treatment.

Thrombocytopenia

Mild to moderate thrombocytopenia (platelet count 50,000–150,000/μL) develops in about 20–40% of patients with APS. Spontaneous bleeding is usually rare, but differentiation from immune thrombocytopenia (ITP) is necessary. Thrombocytopenia may paradoxically increase the risk of thrombosis.

Other clinical features

Skin findings may include livedo reticularis and skin ulcers. Neurological symptoms reported include cognitive impairment, headache (including migraine), epilepsy, and chorea. Cardiac valve disease (Libman-Sacks endocarditis), nephropathy, and adrenal insufficiency may also be associated with APS.

7. Signs

Physical examination findings

Livedo reticularis: a reticular violaceous discoloration of the skin reflecting vascular occlusion. Swelling, erythema, and tenderness at the site of deep vein thrombosis. Focal neurological deficits due to stroke (hemiparesis, dysarthria, etc.). Valvular murmurs may be heard on cardiac auscultation. Splenomegaly is rarely present.

Laboratory findings

Prolongation on lupus anticoagulant (LA) testing (dRVVT, aPTT-based). Anticardiolipin antibodies (aCL IgG/IgM) at medium or high titer (>40 GPL or MPL units, or >99th percentile). Anti-β2GPI antibodies (IgG/IgM) >99th percentile. Thrombocytopenia, positive direct Coombs test (when accompanied by autoimmune hemolytic anemia). Isolated aPTT prolongation (not corrected on mixing study) is characteristic.

Imaging findings

Multiple ischemic strokes and white matter changes observed on brain MRI/MRA. Libman-Sacks endocarditis (valve thickening, nodules) on echocardiography. Deep vein thrombosis confirmed by lower-extremity venous ultrasound or CT venography. Pulmonary embolism confirmed by pulmonary CT angiography.

8. Screening

Screening targets

Antiphospholipid antibody screening is recommended in the following cases: ① patients with unexplained venous thromboembolism, ② unexplained arterial thrombosis at a young age under 50 years, ③ thrombosis at atypical sites (mesenteric, hepatic vein, renal vein, etc.), ④ recurrent miscarriage (3 or more times before 10 weeks of gestation), ⑤ unexplained fetal death after 10 weeks of gestation, ⑥ unexplained thrombocytopenia, ⑦ when thrombosis or obstetric complications occur in autoimmune diseases such as SLE.

Basic screening tests

It is recommended to test for all 3 antibodies: lupus anticoagulant testing (dRVVT, aPTT-based), anticardiolipin antibodies (aCL IgG/IgM ELISA), and anti-β2GPI antibodies (IgG/IgM ELISA). All tests should be reconfirmed at an interval of 12 weeks or more after the first positive result to exclude transient antibody positivity.

Testing availability in Korea

At tertiary hospitals in Korea, all 3 antiphospholipid antibody tests are available and covered by health insurance, so access is good. Lupus anticoagulant testing is performed in specialized laboratories, and caution is needed in interpreting test results while taking anticoagulants.

9. Diagnosis

Sydney diagnostic criteria (2006, Miyakis et al.)

The diagnosis of APS requires that at least 1 clinical criterion and at least 1 laboratory criterion be met.

CategoryCriteriaDetails
Clinical criterion ①Vascular thrombosisArterial, venous, or small-vessel thrombosis confirmed by imaging or histology on 1 or more occasions
Clinical criterion ②Pregnancy morbidity (a)1 or more unexplained deaths of a morphologically normal fetus after 10 weeks of gestation
Clinical criterion ②Pregnancy morbidity (b)Premature birth before 34 weeks of gestation due to preeclampsia/eclampsia/placental insufficiency
Clinical criterion ②Pregnancy morbidity (c)3 or more consecutive unexplained spontaneous miscarriages before 10 weeks of gestation
Laboratory criterion ①Lupus anticoagulant (LA) positivePositive on 2 or more occasions 12 weeks apart
Laboratory criterion ②aCL IgG/IgM at medium or high titer>40 GPL/MPL or >99th percentile, on 2 or more occasions 12 weeks apart
Laboratory criterion ③Anti-β2GPI IgG/IgM >99th percentilePositive on 2 or more occasions 12 weeks apart

Antibody risk classification (high-risk triple positivity)

Positivity for all 3 antibodies, LA, aCL, and anti-β2GPI (triple positivity), defines the high-risk group with the highest risk of recurrent thrombosis and obstetric complications. Single antibody positivity, especially isolated low-titer aCL positivity, has a low association with clinical APS.

Differential diagnosis

Differentiation is needed from inherited thrombophilia (Factor V Leiden, prothrombin G20210A, protein C, protein S, or antithrombin deficiency), homocysteinemia, polycythemia vera/essential thrombocythemia, thrombotic thrombocytopenic purpura (TTP), heparin-induced thrombocytopenia (HIT), and others.

10. Treatment

Anticoagulation for thrombotic APS

In patients with APS who have had venous thromboembolism, long-term anticoagulation is given with a vitamin K antagonist (warfarin), with a target INR of 2.0–3.0. When arterial thrombosis (especially stroke) has occurred, maintaining a target INR of 2.0–3.0 or adding aspirin is considered. Because the TRAPS trial showed that direct oral anticoagulants (DOACs) carry a higher risk of thrombosis recurrence than warfarin in triple-positive high-risk APS, they are currently not recommended in high-risk APS.

Treatment of obstetric APS

In patients with APS during pregnancy, the combination of low-dose aspirin (75–100 mg/day) and prophylactic or therapeutic doses of low-molecular-weight heparin (LMWH) is the standard treatment. This combination therapy improves the live birth rate to about 70–80%. Because warfarin has fetal toxicity in early pregnancy (especially weeks 6–12), it is replaced by LMWH during pregnancy.

Prevention of recurrence and long-term management

To prevent thrombosis recurrence, modifiable risk factors (smoking, oral contraceptives, obesity, hypertension) are actively managed. Hydroxychloroquine has an effect in preventing thrombosis recurrence in patients with APS accompanied by SLE and is generally recommended. Statins are being studied for their benefit in APS because of their vascular endothelial protective effects.

Catastrophic APS (CAPS)

A rare severe form in which multiple organ thromboses occur within a short period. It is treated with a combination of anticoagulants, high-dose steroids, plasma exchange, intravenous immunoglobulin (IVIG), and rituximab. It is an emergency with a mortality rate of about 30–50%, requiring immediate intensive care.

11. Prognosis

Risk of thrombosis recurrence

When anticoagulation is discontinued, the rate of thrombosis recurrence within the first 2 years reaches about 50%. The risk of recurrence is highest with triple positivity (LA + aCL + anti-β2GPI all positive), arterial thrombosis, accompanying SLE, and 2 or more previous thrombotic events. In single-antibody positivity and low-risk groups, the risk of recurrence is relatively low.

Long-term prognosis

APS is a chronic disease, and appropriate anticoagulation can prevent much of the recurrence of thrombosis. However, bleeding complications of long-term warfarin therapy, management of cardiovascular risk factors, and neurocognitive decline affect the long-term prognosis. In patients with APS accompanied by SLE, worsening of the prognosis due to complications of SLE itself must also be considered.

Obstetric prognosis

With appropriate treatment (aspirin + LMWH), the live birth rate is about 70–80%. When recurrent pregnancy loss persists despite treatment, rescue therapies such as adding hydroxychloroquine, rIVIg, and plasma exchange are considered.

12. Prevention

Primary prevention

In those who are antiphospholipid antibody positive but do not meet the criteria for clinical APS (asymptomatic carriers), low-dose aspirin is recommended for high-risk groups (triple positivity, accompanying SLE, multiple cardiovascular risk factors). It is important to eliminate additional thrombotic risk factors such as smoking, obesity, and oral contraceptive use.

Secondary prevention

In patients with APS who have had thrombosis, maintaining long-term anticoagulation (warfarin) is key. Regular INR monitoring, maintenance of the therapeutic INR range, and surveillance for bleeding complications are necessary. Discontinuation of anticoagulation should be decided after thorough consultation with a specialist.

Precautions during infection and surgical procedures

In patients with APS, careful attention to anticoagulant management is needed in triggering situations such as surgery, infection, and delivery. In particular, when anticoagulants must be temporarily discontinued, bridging anticoagulation should be considered.

13. References

  1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006;4(2):295-306.
  2. Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed). 1983;287(6399):1088-1089.
  3. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498-1509.
  4. Sammaritano LR. Antiphospholipid syndrome. Best Pract Res Clin Rheumatol. 2020;34(1):101463.
  5. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237-242.
  6. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304.
  7. Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2(22):3317-3359.
  8. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019-1027.
  9. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378(21):2010-2021.
  10. Dobrowolski C, Erkan D. Treatment of antiphospholipid syndrome beyond anticoagulation. Curr Rheumatol Rep. 2017;19(7):42.
  11. Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, et al. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases. Autoimmun Rev. 2015;14(5):387-395.
  12. Rodgers GM, Tokars JI. Antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2004:432-436.